<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04314869</url>
  </required_header>
  <id_info>
    <org_study_id>TUX2020</org_study_id>
    <nct_id>NCT04314869</nct_id>
  </id_info>
  <brief_title>Uterus Transplantation Procedure From a Live Donor</brief_title>
  <official_title>Feasibility Study of Uterus Transplantation Procedure From a Live Donor Obtaining the Graft by Laparoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital Clinic of Barcelona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital Clinic of Barcelona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Absolut uterine factor, meaning the absence of uterus, represents a cause for sterility&#xD;
      without the possibility of a present treatment. The uterine factor affects millions of women&#xD;
      and may be due to congenital problems, such as the Muller anomalies (Mayer Rockitansky&#xD;
      Syndrome) or acquired by previous hysterectomy or intrauterine adhesions (Asherman's&#xD;
      Syndrome). The uterine transplant would represent the only possibility for patients with an&#xD;
      absolute uterine factor to achieve both genetic and gestational maternity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To obtain by laparoscopy a viable uterus for transplantation from a living donor is feasible.&#xD;
      The laparoscopic procedure increases safety and provides the benefits of minimally invasive&#xD;
      surgery to the grafting technique already described by laparotomy. The objective of the&#xD;
      present study is to develop a pilot program in the transplant of a living donor. We include 5&#xD;
      pairs of uterine donor-transplant recipients indicated for sterility by absolute uterine&#xD;
      factor due to Mayer Rokitansky Syndrome. Patients will undergo surgery for this transplant&#xD;
      and after 6 months of it with correct function of the graft, embryos will be transferred in&#xD;
      order to achieve pregnancy. C-section will be performed for delivery. The attempt of two&#xD;
      gestations (if there are sufficient cryopreserved embryos for a second gestation) and&#xD;
      withdrawing the graft (hysterectomy) and, therefore, immunosuppression is agreed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2020</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of grafts obtained by laparoscopy</measure>
    <time_frame>2 years</time_frame>
    <description>It is feasible to obtain the graft by laparoscopy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of healthy newborns</measure>
    <time_frame>5 years</time_frame>
    <description>A healthy newborn after C-section</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Rokitansky Kuster Hauser Syndrome</condition>
  <condition>Sterility, Female</condition>
  <arm_group>
    <arm_group_label>Recipient</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient with absolut uterine factor will undergo uterus transplantation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Uterus transplantation</intervention_name>
    <description>Patient will undergo surgery in order to transplant the graft (uterus). After that, a follow-up in order to detect early rejection. After 6 months, embryo transfer will be perfomed. Labour route will be C-Section. Two pregnancies are agreed, and after the second one, a hysterectomy will be performed in order to remove the graft.</description>
    <arm_group_label>Recipient</arm_group_label>
    <other_name>Ovarian estimulation</other_name>
    <other_name>Immunosupression treatment</other_name>
    <other_name>Embryo transfer</other_name>
    <other_name>C-section</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria Recipient:&#xD;
&#xD;
          -  Patient with sterility for absolute uterine factor (malformation or previous surgery&#xD;
             for benign processes).&#xD;
&#xD;
          -  Age &lt;40 years.&#xD;
&#xD;
          -  Absence of pathology that contraindicates a complex surgical process,&#xD;
             immunosuppression or gestation.&#xD;
&#xD;
          -  Positive results to the IVF cycle prior to the surgery, obtaining quality embryos.&#xD;
&#xD;
          -  Acceptance to participate in the study signing the informed consent.&#xD;
&#xD;
        Exclusion Criteria Recipient:&#xD;
&#xD;
          -  Medical or surgical pathology that contraindicates a complex pelvic surgical&#xD;
             procedure.&#xD;
&#xD;
          -  Medical conditions that contraindicate, may aggravate or complicate the&#xD;
             immunosuppressor treatment, such as neoplastic or preneoplasic diseases, chronic&#xD;
             infectious diseases, autoimmune diseases, renal or liver failure.&#xD;
&#xD;
          -  Medical or surgical pathology that contraindicates pregnancy.&#xD;
&#xD;
          -  Anatomic alterations or vascular pathology that might difficult the vascular&#xD;
             anastomosis: severe endometriosis, pelvic kidney, severe adherence syndrome or others.&#xD;
&#xD;
          -  Uncontrolled psychopathology.&#xD;
&#xD;
        Inclusion Criteria donor:&#xD;
&#xD;
          -  Age &lt;65 years.&#xD;
&#xD;
          -  First- or second-degree relatives.&#xD;
&#xD;
          -  Completed reproductive desire.&#xD;
&#xD;
          -  History of previous pregnancies and births.&#xD;
&#xD;
          -  Absence of associated pathology that contraindicates prolonged and complex&#xD;
             laparoscopic surgery (pneumopathies, heart disease, morbid obesity, â€¦).&#xD;
&#xD;
          -  Acceptance to participate in the study signing the informed consent&#xD;
&#xD;
        Exclusion Criteria donor:&#xD;
&#xD;
          -  Potential future pregnancy desire.&#xD;
&#xD;
          -  Surgery for the treatment of gender identity disorder.&#xD;
&#xD;
          -  Infections: HIV or risk group, HBV-DNA and / or HBsAg positive, positive HCV, active&#xD;
             bacterial sepsis, infections with multi-resistant bacteria, active tuberculosis or&#xD;
             incomplete treatment of the same, Chagas disease, untreated active viral infections.&#xD;
&#xD;
          -  Active malignant cancer of any location, except skin basal cell carcinoma. Treated&#xD;
             cancer without current evidence of illness but with a follow-up of less than 5 years.&#xD;
&#xD;
          -  Benign pelvic pathology: uterine fibroids, uterine malformations, severe&#xD;
             endometriosis, severe adherence syndrome.&#xD;
&#xD;
          -  Vascular pathology: malformations, atheromatosis, hypertensive or diabetic&#xD;
             vasculopathy, connective tissue disease with vascular involvement.&#xD;
&#xD;
          -  Premalignant pelvic pathology: pre-invasive cervical and/or vaginal, endometrial&#xD;
             hyperplasia.&#xD;
&#xD;
          -  BRCA mutation carriers or genes related to Lynch syndrome.&#xD;
&#xD;
          -  History of implantation failure or multiple abortions of unknown cause.&#xD;
&#xD;
          -  Contraindications for the surgical procedure of donation through laparoscopy: diabetes&#xD;
             mellitus, liver disease, nephropathy, heart disease, pneumopathy, morbid obesity or&#xD;
             high-risk cardiovascular factors.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>It is a uterus transplantation program, it only includes women.</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francisco Carmona, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mariona Rius, MD</last_name>
    <phone>932275400</phone>
    <phone_ext>5436</phone_ext>
    <email>marius@clinic.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francisco Carmona, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 17, 2020</study_first_submitted>
  <study_first_submitted_qc>March 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2020</study_first_posted>
  <last_update_submitted>November 7, 2020</last_update_submitted>
  <last_update_submitted_qc>November 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hospital Clinic of Barcelona</investigator_affiliation>
    <investigator_full_name>Francisco Carmona</investigator_full_name>
    <investigator_title>Head of Gynecology Department</investigator_title>
  </responsible_party>
  <keyword>minimally invasive surgery</keyword>
  <keyword>uterus transplantation</keyword>
  <keyword>living donor</keyword>
  <keyword>absolut uterine factor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infertility</mesh_term>
    <mesh_term>Infertility, Female</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>We will not share individual participant data, but we will publish all the results and protocols so other researchers have access to this information</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

